Avance (2021a). NPV vs rNPV. Disponible à l’adresse suivante : https://avance.ch/download/npv-vs-rnpv/.
Avance (2021b). Discount rates in drug development. Disponible à l’adresse suivante : https://avance.ch/download/discount-rates-in-pharma-and-biotech/.
Biotechnology Innovation Organization (2021). Clinical development success rates and contributing factors 2011–2020. Informa Pharma Intelligence, QLS advisors.
Black, F. et M. Scholes (1973). The Pricing of Options and Corporate Liabilities. Journal of Political Economy, 81(3), pages 637–654. http://www.jstor.org/stable/1831029.
Bogdan, B. et R. Villiger (2010). Valuation in Life Sciences. 3e éd. Berlin, Heidelberg : Springer.
Chance, D.M. et P.P. Peterson (2002). Real Options and Investment Valuation. The Research Foundation of the Association for Investment Management and Research (désormais dénommé Chartered Financial Analyst Institute).
Clinical Research (2019). Cost of Clinical Trials: A Breakdown (Infographic). Disponible à l’adresse suivante : www.clinicalresearch.io/blog/industry-trends/cost-of-clinical-trials-breakdown.
Cook, A. (2016). Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them.. 2e éd. Londres : Gower.
Copeland, T. et V. Antikarov (2001). Real Options – A Practitioners’ Guide. New York : Texere.
Schlander, M. et al. (2021). How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics, 39(11), pages 1243–1269. doi.org/10.1007/s40273-021-01065-y.